Baseline characteristics and clinical outcomes according to ‘Boolean remission’ measured after 4 months
| ‘Boolean remission’ n=144 | No ‘Boolean remission’ n=420 | p Value | |
|---|---|---|---|
| Baseline | |||
| Age (years), mean±SD | 51.2±14.3 | 51.8±13.9 | 0.662 |
| Female, n (%) | 89 (62) | 290 (69) | 0.110 |
| RA (2010), n (%) | 114 (79) | 327 (78) | 0.707 |
| DAS, mean±SD | 3.05±0.91 | 3.28±0.92 | 0.008 |
| HAQ, mean±SD | 1.04±0.67 | 1.21±0.65 | 0.007 |
| Symptom duration (in weeks), median (IQR) | 17 (8.8–34) | 17.5 (9–32) | 0.784 |
| RF positive, n (%) | 88 (61) | 228 (54) | 0.139 |
| ACPA positive, n (%) | 86 (60) | 223 (53) | 0.106 |
| Anti-CarP, n (%) | 47 (33) | 116 (28) | 0.166 |
| ESR mm/h, median (IQR) | 26.5 (11.5–36.8) | 24 (11–41) | 0.596 |
| SJC, median (IQR) | 5 (2.3–10) | 6 (3–10) | 0.796 |
| TJC, median (IQR) | 5 (4–8) | 7 (4–11) | <0.001 |
| Total SHS, median (IQR) | 0 (0–0) | 0 (0–0) | 0.714 |
| Early DAS remission 4 months, n (%) | 144 (100) | 226 (54) | <0.001 |
| Arm 1, n (%) | 0 (0) | 77 (18) | <0.001 |
| Arm 2, n (%) | 0 (0) | 71 (17) | <0.001 |
| OP (%) | 0 (0) | 46 (11) | <0.001 |
| 2 years | |||
| DAS, mean±SD | 1.11±0.75 | 1.61±0.83 | <0.001 |
| HAQ, mean±SD | 0.29±0.44 | 0.64±0.61 | <0.001 |
| Total SHS, median (IQR) | 0 (0–0.5) | 0 (0–0.5) | 0.939 |
| SHS progression, median (IQR) | 0 (0–0) | 0 (0–0) | 0.357 |
| SHS progression, n (%) | 16 (11) | 31 (7) | 0.264 |
| DAS remission, n (%) | 103 (72) | 186 (44) | <0.001 |
| Drug-free remission, n (%) | 51 (35) | 72 (17) | <0.001 |
| ACR/EULAR remission, n (%) | 67 (47) | 63 (15) | <0.001 |
ACPA, anticitrullinated protein antibodies; Anti-CarP, anticarbamylated protein antibodies; ACR, American College of Rheumatology; DAS, disease activity score; ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; HAQ, health assessment questionnaire; OP, out of protocol group; RA, rheumatoid arthritis; RF, rheumatoid factor; SHS, Sharp/van der Heijde score; SJC, swollen joint count; TJC, tender joint count.